About

Element Biosciences focuses on next-generation sequencing (NGS) technology, offering the AVITI System, a compact benchtop device that provides high-quality sequencing at a low cost of $1 per million reads. This system is designed for accuracy and efficiency, catering to clients like academic researchers and pharmaceutical companies. Element Biosciences stands out by partnering with other biotech firms, such as QIAGEN, to provide complete NGS workflows and by offering the 2023 AVITI for All Grant, which gives free sequencing for various applications. The company's goal is to make high-quality sequencing accessible and affordable for a diverse range of users.

Simplify's Take

What believers are saying

• Element Biosciences raised $277M in Series D funding, supporting AVITI commercialization.
• Record growth in AVITI System installations shows strong market acceptance and expansion.
• Trinity innovation streamlines genomic research, enhancing product offerings and market position.

What critics are saying

• Competition from Illumina and startups pressures Element to innovate and reduce costs.
• Reliance on partnerships like QIAGEN and Revvity poses risks if partnerships dissolve.
• Investment in AVITI24 and Trinity may not yield expected returns if adoption is slow.

What makes Element Biosciences unique

• Element Biosciences offers the AVITI System, a cost-effective benchtop DNA sequencer.
• The company's LoopSeq technology enhances sequencing accuracy by avoiding index hopping errors.
• Partnerships with QIAGEN and Revvity provide comprehensive NGS workflows and neonatal testing.

Help us improve and share your feedback! Did you find this helpful?

YesNo